The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 06, 2018

Filed:

Sep. 14, 2016
Applicants:

Vanderbilt University, Nashville, TN (US);

Yale University, New Haven, CT (US);

Inventors:

David G. Harrison, Nashville, TN (US);

Kim Ramil Montaniel, Antioch, TN (US);

Kasey C. Vickers, Franklin, TN (US);

Jing Wu, Lexington, KY (US);

Jay D. Humphrey, Madison, CT (US);

Matthew R. Bersi, Nashville, TN (US);

Assignees:

Vanderbilt University, Nashville, TN (US);

Yale University, New Haven, CT (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 45/06 (2006.01); A61K 31/7105 (2006.01); C12Q 1/6883 (2018.01); A61B 17/22 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/7105 (2013.01); A61K 45/06 (2013.01); C12Q 1/6883 (2013.01); A61B 17/22 (2013.01); A61B 2017/22001 (2013.01); A61B 2017/22051 (2013.01); C12N 2310/113 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3231 (2013.01); C12N 2320/31 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01);
Abstract

Methods, compositions, devices, and kits for treating and/or reducing the risk of developing a condition associated with fibrosis and/or collagen deposition are provided. The method of treating and/or reducing the risk of developing a condition associated with fibrosis and/or collagen deposition in a subject includes administering an effective amount a miRNA-762 inhibitor to the subject, wherein the subject is identified as having a risk of developing and/or a need for treatment of the condition associated with fibrosis and/or collagen deposition. The kit includes a vial containing an miRNA-762 inhibitor and a device for use in a surgery creating a risk of fibrosis and/or collagen deposition. The composition includes a pharmaceutical composition comprising a miRNA-762 inhibitor and a second agent selected from the group consisting of: an angiotensin-converting enzyme (ACE) inhibitors, an angiotensin receptor blocker (ARB), another antihypertensive agent, a steroid, and combinations thereof.


Find Patent Forward Citations

Loading…